OKYO
OKYO Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$1.36
+3.03%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.37
From 52W high−56.27%
Volume22106.00
Market cap$71.37M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.37
From 52W high
−56.27%
Volume
22106.00
Market cap
$71.37M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.5x
P/E (TTM)
—
RSI (14)
37.0
MomentumView details →
1D Return
+3.03%
YTD Return
−35.02%
SummaryUpdated Mar 1, 2026
OKYO Pharma Limited (NASDAQ:OKYO) is a preclinical biopharmaceutical company founded in 2007 and headquartered in London, United Kingdom. The company went public on May 17, 2022, and focuses on developing innovative therapeutics for patients suffering from inflammatory eye diseases and ocular pain. As a preclinical-stage company, OKYO Pharma has not yet generated revenue and is currently advancing its pipeline of ophthalmic treatments through research and development phases.
Similar companies
Latest newsMore news →
OKYO Pharma Non-Executive Director John Brancaccio purchased 5,000 ordinary shares of the company on NASDAQ at $1.48 per share.59d agoOKYO Pharma CEO Robert J. Dempsey purchased 15,000 ordinary shares on NASDAQ at $1.54 per share.59d agoOKYO Pharma received positive FDA feedback from a Type D meeting supporting advancement of urcosimod into a Phase 3 trial for neuropathic corneal pain.74d ago